Company intelligence / Profile preview

Shanghai Belief-Delivery BioMed Co., Ltd.

Shanghai City, Shanghai Shi, Chinabeliefbiomed.com ↗

Ownership: Private
Development stage: Phase 3

Overview

BBM-H901, an AAV gene therapy for Hemophilia B, has completed Phase III patient dosing with positive results—100% of patients stopped Factor IX treatment, annual bleeding rate reduced to zero, coagulation factors increased and persisted with no serious adverse events reported. Other programs are at various clinical/preclinical stages targeting rare genetic disorders and age-related diseases [3].

Therapeutic areas: OncologyRheumatologyRare DiseasesHematology
Modalities: AAV-based gene therapy[3]
Industry: Biotech

Drug pipeline

1 asset

BBM-H901

Phase 3

Indications: Hemophilia B

Partnerships

Takeda China – exclusive commercial partnership for certain products in China market [7]

Beyond the preview

Go deeper on Shanghai Belief-Delivery BioMed Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Belief-Delivery BioMed Co., Ltd..

Explore the full profile